Literature DB >> 24111951

Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis.

Wei Ding1, Tait D Shanafelt, Connie E Lesnick, Charles Erlichman, Jose F Leis, Charla Secreto, Traci R Sassoon, Timothy G Call, Deborah A Bowen, Michael Conte, Shaji Kumar, Neil E Kay.   

Abstract

Entities:  

Keywords:  Akt; B cell receptor; chronic lymphocytic leukaemia; cytokine

Mesh：

Substances：

Year:  2013        PMID： 24111951      PMCID： PMC3975807          DOI： 10.1111/bjh.12564

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.

Authors:  Jan A Burger; Maite P Quiroga; Elena Hartmann; Andrea Bürkle; William G Wierda; Michael J Keating; Andreas Rosenwald
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

2.  Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Authors:  Sarah E M Herman; Amber L Gordon; Amy J Wagner; Nyla A Heerema; Weiqiang Zhao; Joseph M Flynn; Jeffrey Jones; Leslie Andritsos; Kamal D Puri; Brian J Lannutti; Neill A Giese; Xiaoli Zhang; Lai Wei; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

3.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

4.  CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.

Authors:  Mariela Sivina; Elena Hartmann; Thomas J Kipps; Laura Rassenti; Diana Krupnik; Susan Lerner; Ruth LaPushin; Lianchun Xiao; Xuelin Huang; Lillian Werner; Donna Neuberg; Hagop Kantarjian; Susan O'Brien; William G Wierda; Michael J Keating; Andreas Rosenwald; Jan A Burger
Journal:  Blood       Date:  2010-11-29       Impact factor: 22.113

5.  Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

Authors:  Kirsten Fischer; Paula Cramer; Raymonde Busch; Stephan Stilgenbauer; Jasmin Bahlo; Carmen D Schweighofer; Sebastian Böttcher; Peter Staib; Michael Kiehl; Michael J Eckart; Gabriele Kranz; Valentin Goede; Thomas Elter; Andreas Bühler; Dirk Winkler; Michael Kneba; Hartmut Döhner; Barbara F Eichhorst; Michael Hallek; Clemens-Martin Wendtner
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

6.  Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch.

Authors:  Wei Ding; Traci R Knox; Renee C Tschumper; Wenting Wu; Susan M Schwager; Justin C Boysen; Diane F Jelinek; Neil E Kay
Journal:  Blood       Date:  2010-07-06       Impact factor: 22.113

7.  First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

Authors:  Timothy A Yap; Li Yan; Amita Patnaik; Ivy Fearen; David Olmos; Kyriakos Papadopoulos; Richard D Baird; Liliana Delgado; Adekemi Taylor; Lisa Lupinacci; Ruth Riisnaes; Lorna L Pope; Simon P Heaton; George Thomas; Michelle D Garrett; Daniel M Sullivan; Johann S de Bono; Anthony W Tolcher
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

8.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

9.  Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells.

Authors:  J Edelmann; L Klein-Hitpass; A Carpinteiro; A Führer; L Sellmann; S Stilgenbauer; U Dührsen; J Dürig
Journal:  Leuk Res       Date:  2008-04-14       Impact factor: 3.156

10.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
  10 in total
  13 in total

1.  Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.

Authors:  Jeremy T Larsen; Tait D Shanafelt; Jose F Leis; Betsy LaPlant; Tim Call; Adam Pettinger; Curtis Hanson; Charles Erlichman; Thomas Matthew Habermann; Craig Reeder; Daniel Nikcevich; Deborah Bowen; Michael Conte; Justin Boysen; Charla Secreto; Connie Lesnick; Renee Tschumper; Diane Jelinek; Neil E Kay; Wei Ding
Journal:  Am J Hematol       Date:  2017-06-01       Impact factor: 10.047

2.  Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.

Authors:  Hemant Sarin
Journal:  Mol Clin Oncol       Date:  2015-12-16

3.  AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.

Authors:  Emilio Cosimo; Anuradha Tarafdar; Michael W Moles; Ailsa K Holroyd; Natasha Malik; Mark A Catherwood; Jodie Hay; Karen M Dunn; Alan M Macdonald; Sylvie M Guichard; Declan O'Rourke; Michael T Leach; Owen J Sansom; Sabina C Cosulich; Alison M McCaig; Alison M Michie
Journal:  Clin Cancer Res       Date:  2018-12-17       Impact factor: 12.531

Review 4.  Targeting PI3K/AKT/mTOR network for treatment of leukemia.

Authors:  Jessika Bertacchini; Nazanin Heidari; Laura Mediani; Silvano Capitani; Mohammad Shahjahani; Ahmad Ahmadzadeh; Najmaldin Saki
Journal:  Cell Mol Life Sci       Date:  2015-02-25       Impact factor: 9.261

5.  MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.

Authors:  Jeng-Wei Lu; Yu-Min Lin; Yen-Ling Lai; Chien-Yuan Chen; Chung-Yi Hu; Hwei-Fang Tien; Da-Liang Ou; Liang-In Lin
Journal:  Med Oncol       Date:  2015-06-19       Impact factor: 3.064

6.  Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells.

Authors:  Neil E Kay; Traci Sassoon; Charla Secreto; Sutapa Sinha; Tait D Shanafelt; Asish K Ghosh; Jack L Arbiser
Journal:  Leuk Lymphoma       Date:  2016-05-17

Review 7.  Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date.

Authors:  Kyle Crassini; Stephen P Mulligan; O Giles Best
Journal:  World J Clin Cases       Date:  2015-08-16       Impact factor: 1.337

8.  Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia.

Authors:  Elinor A Chapman; Melanie Oates; Ishaque S Mohammad; Barry R Davies; Paul K Stockman; Jianguo Zhuang; Andrew R Pettitt
Journal:  Oncotarget       Date:  2017-11-07

9.  [Advances in leukemia inhibitors targeting PI3K/AKT/mTOR pathway].

Authors:  Le Wang; Yajing Chu; Tao Cheng; Weiping Yuan
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2015-10

10.  A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells.

Authors:  Marco Breinig; Felix A Klein; Wolfgang Huber; Michael Boutros
Journal:  Mol Syst Biol       Date:  2015-12-23       Impact factor: 11.429
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.